Silver Book Fact

Cost of pneumonia vaccine

Addition of PCV13 (13-valent pneumococcal conjugate vaccine) to previously recommended pneumococcal polysaccharide vaccine for immunocompromised adults cost $70,937 per quality adjusted life year compared to no vaccine.

Smith K, Nowalk M, Raymund M, Zimmerman R. Cost-Effectiveness of Pneumococcal Conjugate Vaccination in Immunocompromised Adults. Vaccine. 2013; 31(37): 3950-6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742552/

Reference

Title
Cost-Effectiveness of Pneumococcal Conjugate Vaccination in Immunocompromised Adults
Publication
Vaccine
Publication Date
2013
Authors
Smith K, Nowalk M, Raymund M, Zimmerman R
Volume & Issue
Volume 31, Issue 37
Pages
3950-6
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Pre-surgery antibiotic use reduces 6-day mortality by 50% in elderly
    Effective pre-surgery antibiotic use can reduce 60-day mortality in the elderly by 50%.  
  • Shingles vaccine would reduce healthcare use
    Use of the shingles vaccine in immunocompetent adults could eliminate more than 300,000 outpatient visits, 375,000 prescriptions, 9,700 emergency room visits, and 10,000 hospitalizations.  
  • Reduction in hospital-acquired HAIs could produce significant savings
    Practices that lead to a 20% reduction in preventable hospital-acquired HAIs would save up to $6.8 billion in medical costs. a 70% reduction would lead to a savings of up…  
  • Potential savings from shingles vaccine
    Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles,…  
  • Flu vaccine use reduces disease burden
    Use of the LAIV (live attenuated influenza virus) in healthy adults ages 18 to 64 reduced febrile illness by 19% and upper respiratory tract illnesses by 24%. It also…